Limits of Tumorectomy in clinical localized renal cell cancer：在临床局限性肾细胞癌的肿瘤切除术的限制.pptVIP

下载本文档

4
0
约1.18万字
约 55页
2017-12-11 发布于湖北
举报
版权申诉

Limits of Tumorectomy in clinical localized renal cell cancer：在临床局限性肾细胞癌的肿瘤切除术的限制.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Limits of Tumorectomy in clinical localized renal cell cancer：在临床局限性肾细胞癌的肿瘤切除术的限制

* * * * * * * * * * * * 20% 40% 60% 80% 100% 0 12 24 36 48 months D + E M + P no. at Risk 338 336 217 235 median survival (months) 18 16 HR: 0.80 (95% CI 0.67, 0.97), p = 0.01 med. F/U: 1 J docetaxel chemotherapy overall survival SWOG 9916 no (n) died Petrylak et al, N Engl J Med 2004 SWOG 99-16 Petrylak J NCI 2006 Survival in subgroupsdocetaxel 3 weekly vs mitoxantrone 0.2 0.4 0.6 0.8 1 1.2 1.4 Intent to Treat age 65 age ≥ 65 age ≥ 75 pain no pain yes KPS ≥ 80 KPS ≤ 70 hazard ratio in favour of docetaxel mitoxantrone Tannock et al, N Engl J Med 2004 Cochrane Reviewchemotherapy of HRPC n=6929 patients; 47 studies investigated substances: EMP docetaxel 5-FU cyclophosphamide doxorubicine mitoxantrone vinorelbine Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006 Cochrane Review PSA response (50%): EMP 48% docetaxel 52% 5-FU 20% cyclophosphamide n.d. doxorubicine 50% (CAVE: only 1 study!) mitoxantrone 33% vinorelbine n.d. Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006 only DOC = overall survival ↑ (2.5 months) pain ↓ DOC Mit + Pred quality of life ↑ DOC Mit + Pred results authors‘ conclusion: ?At the present time this* probably represents the best chemotherapeutic regime available for men with HRPC“ *- docetaxel q3w Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006 secondary hormone manipulation or chemotherapy? secondary hormone manipulation chemotherapy CALGB9583 SWOG 9916 TAX-327 AAW + Ketokonazol EMP docetaxel vs MP DP q3w vs DP q1w vs MP n 260 770 1006 overall survival in better arm 16.7 months 17.5 months 18.9 months overall survival in worse arm 15.3 months 15.6 months 16.5 months Bellmunt, Eur Urol Suppl 2009 open questions when to start with chemotherapy? should asymptomatic M+ patients be treated? how long to continue treatment? secondary treatment? intermittent chemotherapy? re-exposition? Early vs late chemotherapy? for benefit esta